Ligand id: 9463

Name: navamepent

Structure and Physico-chemical Properties

2D Structure
Click here for structure editor
Calculated Physico-chemical Properties
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 66.76
Molecular weight 304.17
XLogP 2.51
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

Immunopharmacology Comments
A metabolically stable resolvin E1 analogue, that has completed Phase 2 clinical evaluation in several occular inflammation conditions.
Immunopharmacology Disease
Disease X-Refs Comment References
Allergic conjunctivitis Disease Ontology: DOID:11204
Phase 2 clinical trial NCT01639846 has been completed.
keratoconjunctivitis sicca Disease Ontology: DOID:12895
Phase 2 clinical trials NCT00799552 and NCT01675570 are completed.